References:
1. Butler E, Ludwig K, Pacenta HL, Klesse LJ, Watt TC, Laetsch TW.
Recent progress in the treatment of cancer in children. CA Cancer
J Clin . Jul 2021;71(4):315-332. doi:10.3322/caac.21665
2. Scott EC, Baines AC, Gong Y, et al. Trends in the approval of cancer
therapies by the FDA in the twenty-first century. Nat Rev Drug
Discov . Aug 2023;22(8):625-640. doi:10.1038/s41573-023-00723-4
3. Hunger SP, Raetz EA. How I treat relapsed acute lymphoblastic
leukemia in the pediatric population. Blood . Oct 15
2020;136(16):1803-1812. doi:10.1182/blood.2019004043
4. Lin YJ, Mashouf LA, Lim M. CAR T Cell Therapy in Primary Brain
Tumors: Current Investigations and the Future. Frontiers in
Immunology . Feb 21 2022;13doi:ARTN 817296
10.3389/fimmu.2022.817296
5. Del Bufalo F, De Angelis B, Caruana I, et al. GD2-CART01 for Relapsed
or Refractory High-Risk Neuroblastoma. N Engl J Med . Apr 6
2023;388(14):1284-1295. doi:10.1056/NEJMoa2210859
6. Shah NN, Lee DW, Yates B, et al. Long-Term Follow-Up of CD19-CAR
T-Cell Therapy in Children and Young Adults With B-ALL. J Clin
Oncol . May 20 2021;39(15):1650-1659. doi:10.1200/JCO.20.02262
7. Long KB, Young RM, Boesteanu AC, et al. CAR T Cell Therapy of
Non-hematopoietic Malignancies: Detours on the Road to Clinical Success.Front Immunol . 2018;9:2740. doi:10.3389/fimmu.2018.02740
8. Webb JA, Kamal AH, LeBlanc TW. A New Frontier for Palliative Care:
The Need to Train Palliative-Oncology Subspecialists. J Palliat
Med . Dec 2018;21(12):1679-1680. doi:10.1089/jpm.2018.0421
9. Freedman JL, Beeler DM, Bowers A, et al. Supportive Care in Pediatric
Oncology: Opportunities and Future Directions. Cancers (Basel) .
Nov 23 2023;15(23)doi:10.3390/cancers15235549
10. Sampetrean A, Aldea M, Mateus C. Precision medicine’s new frontier:
integrating palliative care at the right time. ESMO Open . Oct
2023;8(5):101632. doi:10.1016/j.esmoop.2023.101632
11. Weaver MS, Heinze KE, Kelly KP, et al. Palliative Care as a Standard
of Care in Pediatric Oncology. Pediatr Blood Cancer . Dec 2015;62
Suppl 5:S829-33. doi:10.1002/pbc.25695
12. Wiener L, Kazak AE, Noll RB, Patenaude AF, Kupst MJ. Standards for
the Psychosocial Care of Children With Cancer and Their Families: An
Introduction to the Special Issue. Pediatr Blood Cancer . Dec
2015;62 Suppl 5:S419-24. doi:10.1002/pbc.25675
13. Temel JS, Shaw AT, Greer JA. Challenge of Prognostic Uncertainty in
the Modern Era of Cancer Therapeutics. J Clin Oncol . Oct 20
2016;34(30):3605-3608. doi:10.1200/JCO.2016.67.8573
14. Maude SL. Tisagenlecleucel in pediatric patients with acute
lymphoblastic leukemia. Clin Adv Hematol Oncol . Oct
2018;16(10):664-666.
15. Ruark J, Mullane E, Cleary N, et al. Patient-Reported
Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen
Receptor T Cell Therapy. Biol Blood Marrow Transplant . Oct 9
2019;doi:10.1016/j.bbmt.2019.09.037
16. Akinola IM, Cusatis R, Pasquini MC, et al. Multi-Stakeholder
Qualitative Interviews to Inform Measurement of Patient Reported
Outcomes After CAR-T. Transplant Cell Ther . Apr 2023;29(4):254
e1-254 e9. doi:10.1016/j.jtct.2023.01.004
17. Whisenant MS, Srour SA, Williams LA, et al. The Unique Symptom
Burden of Patients Receiving CAR T-Cell Therapy. Semin Oncol
Nurs . Dec 2021;37(6):151216. doi:10.1016/j.soncn.2021.151216
18. Steineck A, Wiener L, Mack JW, Shah NN, Summers C, Rosenberg AR.
Psychosocial care for children receiving chimeric antigen receptor (CAR)
T-cell therapy. Pediatr Blood Cancer . May 2020;67(5):e28249.
doi:10.1002/pbc.28249
19. Chakraborty R, Sidana S, Shah GL, Scordo M, Hamilton BK, Majhail NS.
Patient-Reported Outcomes with Chimeric Antigen Receptor T Cell Therapy:
Challenges and Opportunities. Biol Blood Marrow Transplant . May
2019;25(5):e155-e162. doi:10.1016/j.bbmt.2018.11.025
20. Efficace F, Cannella L, Sparano F, et al. Chimeric Antigen Receptor
T-cell Therapy in Hematologic Malignancies and Patient-reported
Outcomes: A Scoping Review. Hemasphere . Dec 2022;6(12):e802.
doi:10.1097/HS9.0000000000000802
21. Stenson CL, Vidrine J, Dewhurst F, Osborne W, Menne T, Stocker R. A
qualitative service evaluation of patient and caregiver experiences of
CAR-T therapy: Recommendations for service development and implications
for palliative care teams. Palliat Med . Feb 2023;37(2):215-220.
doi:10.1177/02692163221138880
22. O’Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for
reporting qualitative research: a synthesis of recommendations.Acad Med . Sep 2014;89(9):1245-51.
doi:10.1097/ACM.0000000000000388
23. Wilson IB, Cleary PD. Linking clinical variables with health-related
quality of life. A conceptual model of patient outcomes. JAMA .
Jan 4 1995;273(1):59-65.
24. Collins JJ, Byrnes ME, Dunkel IJ, et al. The measurement of symptoms
in children with cancer. J Pain Symptom Manage . May
2000;19(5):363-77.
25. Hsieh HF, Shannon SE. Three approaches to qualitative content
analysis. Qual Health Res . Nov 2005;15(9):1277-88.
doi:10.1177/1049732305276687
26. Vaismoradi M, Turunen H, Bondas T. Content analysis and thematic
analysis: Implications for conducting a qualitative descriptive study.Nurs Health Sci . Sep 2013;15(3):398-405. doi:10.1111/nhs.12048
27. Attride-Stirling J. Thematic Networks: an analytic tool for
qualitative research. Qualitative Research . Dec 1, 2001
2001;1(3):385-405. doi:10.1177/146879410100100307
28. Elo S, Kyngas H. The qualitative content analysis process. J
Adv Nurs . Apr 2008;62(1):107-15. doi:10.1111/j.1365-2648.2007.04569.x
29. Burns NaG, S.K. The Practice of Nursing Research: Conduct,
Critique and Utilization . 5th ed. Elsevier Saunders; 2005.
30. Saunders B, Sim J, Kingstone T, et al. Saturation in qualitative
research: exploring its conceptualization and operationalization.Qual Quant . 2018;52(4):1893-1907. doi:10.1007/s11135-017-0574-8
31. Robertson EG, Wakefield CE, Shaw J, et al. Decision-making in
childhood cancer: parents’ and adolescents’ views and perceptions.Support Care Cancer . Nov 2019;27(11):4331-4340.
doi:10.1007/s00520-019-04728-x
32. Sisk BA, Kang TI, Mack JW. The evolution of regret: decision-making
for parents of children with cancer. Support Care Cancer . Mar
2020;28(3):1215-1222. doi:10.1007/s00520-019-04933-8
33. Feifer D, Broden EG, Xiong N, et al. Mixed-methods analysis of
decisional regret in parents following a child’s death from cancer.Pediatr Blood Cancer . Oct 2023;70(10):e30541.
doi:10.1002/pbc.30541
34. Wakefield CE, Hetherington K, Robertson EG, et al. Hopes, concerns,
satisfaction and regret in a precision medicine trial for childhood
cancer: a mixed-methods study of parent and patient perspectives.Br J Cancer . Nov 2023;129(10):1634-1644.
doi:10.1038/s41416-023-02429-1
35. Stewart JL, Mishel MH, Lynn MR, Terhorst L. Test of a conceptual
model of uncertainty in children and adolescents with cancer. Res
Nurs Health . Jun 2010;33(3):179-91. doi:10.1002/nur.20374
36. Sprangers MA. Response-shift bias: a challenge to the assessment of
patients’ quality of life in cancer clinical trials. Cancer Treat
Rev . Jan 1996;22 Suppl A:55-62. doi:10.1016/s0305-7372(96)90064-x
37. Requena ML, Avery M, Feraco AM, Uzal LG, Wolfe J, Dussel V.
Normalization of Symptoms in Advanced Child Cancer: The
PediQUEST-Response Case Study. J Pain Symptom Manage . Apr
2022;63(4):548-562. doi:10.1016/j.jpainsymman.2021.12.009
38. Brammer JE, Braunstein Z, Katapadi A, et al. Early toxicity and
clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy
for lymphoma. J Immunother Cancer . Aug
2021;9(8)doi:10.1136/jitc-2020-002303
39. Newman H, Li Y, Liu H, et al. Impact of poverty and neighborhood
opportunity on outcomes for children treated with CD19-directed CAR
T-cell therapy. Blood . Feb 9 2023;141(6):609-619.
doi:10.1182/blood.2022017866
40. Hall AG, Winestone LE, Sullivan EM, et al. Access to Chimeric
Antigen Receptor T Cell Clinical Trials in Underrepresented Populations:
A Multicenter Cohort Study of Pediatric and Young Adult Acute
Lymphobastic Leukemia Patients. Transplant Cell Ther . Jun
2023;29(6):356 e1-356 e7. doi:10.1016/j.jtct.2023.03.022